Cargando…

The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia

BACKGROUND: A recent study demonstrating the use of Therapeutic Drug Monitoring (TDM) in patients with chronic myeloid leukemia (CML) resulted in a higher response rate with imatinib (IM) than demonstrated in second-generation tyrosine kinase inhibitor studies. The cost-effectiveness of TDM combined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conti, Rena M, Padula, William V, Becker, Russell V, Salamone, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390998/ https://www.ncbi.nlm.nih.gov/pubmed/34337991 http://dx.doi.org/10.18553/jmcp.2021.27.8.1077

Ejemplares similares

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia
por: Kim, Kibum, et al.
Publicado: (2019)

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
por: Padula, William V., et al.
Publicado: (2016)

Prescription drug monitoring and drug overdose mortality
por: Li, Guohua, et al.
Publicado: (2014)

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy
por: Salamone, Sandro, et al.
Publicado: (2022)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Joisten, Carolin, et al.
Publicado: (2023)

Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China
por: Maheshwari, Vikalp Kumar, et al.
Publicado: (2021)

Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?
por: Conti, Rena M., et al.
Publicado: (2018)

The high cost of prescription drugs: causes and solutions
por: Vincent Rajkumar, S.
Publicado: (2020)

Prescription Drug Costs and the Generic Dispensing Ratio
por: Liberman, Joshua N., et al.
Publicado: (2010)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
por: Nakahara, Ryosuke, et al.
Publicado: (2019)

Utilization of the Arkansas Prescription Monitoring Program to combat prescription drug abuse
por: Rittenhouse, Rebecca, et al.
Publicado: (2015)

Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response
por: Sailaja, K., et al.
Publicado: (2012)

Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
por: Izzo, Barbara, et al.
Publicado: (2019)

Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
por: Nakahara, Ryosuke, et al.
Publicado: (2021)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
por: Gebru, Melat T., et al.
Publicado: (2020)

Therapeutic use of Aldara™ in chronic myeloid leukemia
por: Marleau, Annette M, et al.
Publicado: (2007)

Prescription Drug Benefits: Cost Management Issues for Medicare
por: Fox, Peter D.
Publicado: (2003)

Prescription Drug Monitoring Programs and Other Interventions to Combat Prescription Opioid Abuse
por: Chakravarthy, Bharath, et al.
Publicado: (2012)

Impact of prescription drug monitoring program mandate on postoperative opioid prescriptions in children
por: Theodorou, Christina M., et al.
Publicado: (2021)

Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities
por: Gunadi, Christian, et al.
Publicado: (2023)

Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring Program
por: Aroke, Hilary, et al.
Publicado: (2018)

Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method
por: Yang, Xi, et al.
Publicado: (2022)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Drug Repurposing for the Treatment of Acute Myeloid Leukemia
por: Andresen, Vibeke, et al.
Publicado: (2017)

Mechanisms of drug resistance in acute myeloid leukemia
por: Zhang, Jing, et al.
Publicado: (2019)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Recent drug approvals for acute myeloid leukemia
por: Lai, Catherine, et al.
Publicado: (2019)

Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions
por: Lewis, Russell E., et al.
Publicado: (2021)

Drug Target Optimization in Chronic Myeloid Leukemia Using Innovative Computational Platform
por: Chuang, Ryan, et al.
Publicado: (2015)

Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
por: Elsayed, Marwa, et al.
Publicado: (2022)

Impact of a Mandatory Prescription Drug Monitoring Program on Prescription of Opioid Analgesics by Dentists
por: Rasubala, Linda, et al.
Publicado: (2015)

Estimating the Cost of a Medicare Outpatient Prescription Drug Benefit
por: Waldo, Daniel R.
Publicado: (1994)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs
por: Panina, Svetlana B., et al.
Publicado: (2019)

Chinese Intelligence Prescription System improves prescription accuracy while decreasing labor and drug costs
por: Huang, Ting-Yu, et al.
Publicado: (2023)

Managing Heterogeneity in Prescription Drug Coverage Policies
por: Teagarden, J. Russell
Publicado: (2014)

Is karyotyping still needed in the diagnosis and monitoring of chronic myeloid leukemia?
por: Chauffaille, Maria de Lourdes L.F.
Publicado: (2017)

Prescription Drug Monitoring Programs: Examining Limitations and Future Approaches
por: Griggs, Christopher A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7do6r4baslc8sjr057t214me2l